Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Azacitidine 15Cyclophosphamide 13fludarabine phosphate 9Mycophenolic Acid 9Methotrexate 8Antilymphocyte Serum 8venetoclax 7Tacrolimus 7Cyclosporine 7Busulfan 7Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Radiotherapy 5Filgrastim 5Decitabine 5Cord Blood Stem Cell Transplantation 5Rituximab 4Arsenic Trioxide 4Sunitinib 3Sorafenib 3Methylprednisolone 3Melphalan 3Leucovorin 3Clofarabine 3ruxolitinib 2ponatinib 2idelalisib 2Sirolimus 2Moxifloxacin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelomonocytic, Chronic × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡